| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5898079 | Cytokine | 2012 | 7 Pages |
Abstract
⺠Infliximab (IFX) is effective for Crohn's disease treatment. However, antibodies to IFX emerge. ⺠We conducted the study for loss of response (LOR) to IFX and how LOR patients may be treated. ⺠Dose frequency was 8 weeks in responders and 4 weeks in LOR patients, but trough IFX was same. ⺠CDAI and CRP as well as sIL-2R, ANA and CIC were higher in LOR patients. ⺠Granulocyte/monocyte apheresis showed immunormodulatory effects for patients with LOR.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Koji Sono, Akihiro Yamada, Yasushi Yoshimatsu, Nobuo Takada, Yasuo Suzuki,